1. Home
  2. EYPT vs RXT Comparison

EYPT vs RXT Comparison

Compare EYPT & RXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EYPT

EyePoint Pharmaceuticals Inc.

HOLD

Current Price

$13.35

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Logo Rackspace Technology Inc.

RXT

Rackspace Technology Inc.

HOLD

Current Price

$4.48

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
EYPT
RXT
Founded
1987
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
EYPT
RXT
Price
$13.35
$4.48
Analyst Decision
Strong Buy
Hold
Analyst Count
5
6
Target Price
$31.80
$1.71
AVG Volume (30 Days)
724.3K
30.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.13
EPS
N/A
0.03
Revenue
$7,539,000.00
$2,685,700,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3,115.57
$1.35
P/E Ratio
N/A
$143.83
Revenue Growth
N/A
N/A
52 Week Low
$5.57
$0.39
52 Week High
$19.11
$7.65

Technical Indicators

Market Signals
Indicator
EYPT
RXT
Relative Strength Index (RSI) 50.32 56.05
Support Level $12.66 $1.04
Resistance Level $13.32 $7.65
Average True Range (ATR) 0.74 1.12
MACD -0.03 -0.09
Stochastic Oscillator 58.08 44.42

Price Performance

Historical Comparison
EYPT
RXT

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

About RXT Rackspace Technology Inc.

Rackspace Technology Inc is an end-to-end, hybrid, multi-cloud technology services company. It designs, builds, and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services, Data, Colocation, Cloud, Managed Hosting, Professional Services, and Security and Compliance. It has two reportable segments: Private Cloud and Public Cloud. Maximum revenue is generated from the Public Cloud segment, which offers cloud solutions through managed services, elastic engineering, and professional services offerings for customer environments hosted on the AWS, Microsoft Azure, and Google Cloud public cloud platforms. Geographically, the company derives its key revenue from the U.S.

Share on Social Networks: